|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600122819 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-19 04:16:46 |
|
注册时间: Date of Registration: |
2026-04-19 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
高频 QRS 心电分析预测冠心病患者心源性猝死的前瞻性队列研究方案 |
|
Public title: |
High-frequency QRS analysis predicts sudden cardiac death in coronary artery disease: a prospective cohort study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
高频 QRS 心电分析预测冠心病患者心源性猝死的前瞻性队列研究方案 |
|
Scientific title: |
High-frequency QRS analysis predicts sudden cardiac death in coronary artery disease: a prospective cohort study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
付冰奇 |
研究负责人: |
华伟 |
|
Applicant: |
Fu Bingqi |
Study leader: |
Hua Wei |
|
申请注册联系人电话: Applicant telephone: |
+86 10 8839 6966 |
研究负责人电话:
Study leader's |
+86 10 8839 6966 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
bingqifu@163.com |
研究负责人电子邮件: Study leader's E-mail: |
drhuawei@fuwai.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市西城区北礼士路167号 |
研究负责人通讯地址: |
广东省深圳市南山区西丽街道朗山路12号 |
|
Applicant address: |
No. 167, Beili Street, Xicheng District, Beijing |
Study leader's address: |
No. 12, Langshan Road, Xili Subdistrict, Nanshan District, Shenzhen City, Guangdong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国医学科学院阜外医院 |
||
|
Applicant's institution: |
Chinese Academy of Medical Sciences Fuwai Hospital |
||
|
研究负责人所在单位: |
中国医学科学院阜外医院深圳医院 |
||
|
Affiliation of the Leader: |
Fuwai Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
SP2025107(01) |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国医学科学院阜外医院深圳医院伦理委员会生物医学研究及临床试验分委会 |
||
|
Name of the ethic committee: |
The Ethic Committee of Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-07-09 00:00:00 | ||
|
伦理委员会联系人: |
戴志晴 |
||
|
Contact Name of the ethic committee: |
Dai Zhiqing |
||
|
伦理委员会联系地址: |
广东省深圳市南山区西丽街道朗山路12号 |
||
|
Contact Address of the ethic committee: |
No. 12, Langshan Road, Xili Subdistrict, Nanshan District, Shenzhen City, Guangdong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 755 82180028 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
szfwyyirb@126.com |
|
研究实施负责(组长)单位: |
中国医学科学院阜外医院深圳医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省深圳市南山区西丽街道朗山路12号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 12, Langshan Road, Xili Subdistrict, Nanshan District, Shenzhen City, Guangdong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
毕胜普生物科技有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
HyperBio Biological Technology Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
冠状动脉粥样硬化性心脏病;心源性猝死 |
||||||||||||||||||||||
|
Target disease: |
Coronary atherosclerotic heart disease; Cardiac sudden death |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
1. 建立冠心病植入埋藏式心律转复除颤器(ICD)的全国多中心前瞻性队列 2. 评估高频QRS心电分析预测冠心病患者心源性猝死的临床价值,为优化ICD一级预防指征提供科学依据 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Establish a nationwide multicenter prospective cohort of patients with coronary artery disease undergoing implantable cardioverter-defibrillator (ICD) implantation. 2. Evaluate the clinical utility of high-frequency QRS analysis in predicting sudden cardiac death in patients with coronary artery disease, providing scientific evidence to refine the indications for primary prevention ICD implantation. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄>=18 周岁; 2.经冠脉造影确诊的冠心病患者; 3.LVEF<50%; 4. 自愿入组 ,签订知情同意书 ,且遵循保密协议 5.符合下列任意一项则为 ICD 组,不符合下列任意一项则为非 ICD组 6.NYHA II-III 级 、LVEF<=35% , 已接受超过 3 个月的最佳药物治疗; 7.NYHA I 级 、LVEF<=30% , 已接受超过 3 个月的最佳药物治疗; 8.NYHA I 级 、LVEF<=40% , 已接受超过 3 个月的最佳药物治疗、 存在非持续性室速且通过电生理检查诱发出持续性室速。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age >= 18 years old; 2. Patients diagnosed with coronary heart disease through coronary angiography; 3. LVEF < 50%; 4. Voluntary participation, signing the informed consent form, and adhering to the confidentiality agreement; 5. Any one of the following conditions qualifies as the ICD group, and any one of the following conditions does not qualify as the non-ICD group; 6. NYHA II-III grade, LVEF <= 35%, having received the best drug treatment for more than 3 months; 7. NYHA I grade, LVEF <= 30%, having received the best drug treatment for more than 3 months; 8. NYHA I grade, LVEF <= 40%, having received the best drug treatment for more than 3 months, and having non-continuous ventricular tachycardia and inducing continuous ventricular tachycardia through electrophysiological examination. |
||||||||||||||||||||||
|
排除标准: |
1.既往明确发生持续性室速、室颤、心脏骤停的幸存者; 2. 既往已植入心脏植入型电子装置; 3.计划外外科手术; 4.严重肝功能不全: AST-ALT 正常值范围上限 3 倍以上; 严重肾功能不 全: 肾小球滤过率<30 mL/min/1.73m^2 ; 5. 晚期癌症或其他预期寿命< 1 年的重大合并症; 6.妊娠期或哺乳(泌乳)期女性; 7.酗酒或精神心理性疾病; 营养不良: 身体质量指数<= 18 kg/m^2; 8.其它研究者认为受试者不适合参加本临床研究的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Survivors who have previously experienced persistent ventricular tachycardia, ventricular fibrillation, or cardiac arrest; 2. Those who have previously had a cardiac implantable electronic device implanted; 3. Unplanned surgical procedures; 4. Severe liver dysfunction: AST-ALT upper limit of normal value is more than 3 times; Severe kidney dysfunction: Glomerular filtration rate < 30 mL/min/1.73m^2; 5. Advanced cancer or other major comorbidities with an expected lifespan of less than 1 year; 6. Pregnant or lactating (breastfeeding) women; 7. Alcohol abuse or mental and psychological disorders; Malnutrition: Body mass index <= 18 kg/m^2; 8. Other situations where the investigators consider the subjects to be unsuitable for participation in this clinical study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-05-01 00:00:00至 To 2027-04-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-05-01 00:00:00 至 To 2027-04-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |